The editorial method on Semaglutide Compare is simple: separate treatment facts, provider wording, public price claims, support detail and regulatory checks so readers can see which differences are clinical, practical, commercial or likely to change.
The site compares semaglutide routes in layers, not as one blended sales table
Treatment layer
Semaglutide, Wegovy, Ozempic, Rybelsus and oral semaglutide are separated first so the route question stays clear.
Provider layer
Providers are then judged on public wording, visible pricing, delivery detail, support notes and route clarity.
Source layer
Each claim is tied back to the source type that best supports it, rather than treating every page as equally authoritative.
Review layer
Dates stay visible because current provider pages can change more quickly than official treatment guidance.
Treatment, provider, cost and safety are reviewed separately
| Area | What is checked | What remains variable |
|---|---|---|
| Treatment pages | Brand role, route, ingredient context, NHS framing and broad public-access wording. | Licensing, provider uptake and market wording can still evolve over time. |
| Provider pages | Public route wording, listed prices, delivery signals, support notes and visible assessment detail. | Checkout flow, exact availability and any service wording not shown publicly. |
| Comparison pages | The distinction between ingredients, brands, access routes and likely reader intent. | Which route will actually be suitable once a regulated assessment begins. |
| Safety and trust pages | Official guidance, safety notes, legitimacy checks and disclosure standards. | How individual providers interpret and present those details at any given moment. |
What the methodology is trying to avoid
No price-only shortcuts
A first visible fee is not enough if the route, support or delivery basis is still unclear.
No blended route claims
Oral semaglutide, Wegovy and Ozempic should not be compressed into one vague “buy semaglutide” answer.
No false certainty
Suitability, final access and treatment continuation still depend on the provider’s live process and clinical review.